Induced pluripotent stem cells derived from the developing striatum as a potential donor source for cell replacement therapy for Huntington disease
- PMID: 33246883
- PMCID: PMC7822401
- DOI: 10.1016/j.jcyt.2020.06.001
Induced pluripotent stem cells derived from the developing striatum as a potential donor source for cell replacement therapy for Huntington disease
Abstract
Background: Cell replacement therapy (CRT) for Huntington disease (HD) requires a source of striatal (STR) progenitors capable of restoring the function lost due to STR degeneration. Authentic STR progenitors can be collected from the fetal putative striatum, or whole ganglionic eminence (WGE), but these tissues remain impractical for widespread clinical application, and alternative donor sources are required. Here we begin exploring the possibility that induced pluripotent stem cells (iPSC) derived from WGE may retain an epigenetic memory of their tissue of origin, which could enhance their ability to differentiate into STR cells.
Results: We generate four iPSC lines from human WGE (hWGE) and establish that they have a capacity similar to human embryonic stem cells with regard to their ability to differentiate toward an STR phenotype, as measured by expression and demethylation of key STR genes, while maintaining an overall different methylome. Finally, we demonstrate that these STR-differentiated hWGE iPSCs share characteristics with hWGE (i.e., authentic STR tissues) both in vitro and following transplantation into an HD model. Overall, iPSCs derived from human WGE show promise as a donor source for CRT for HD.
Keywords: Huntington disease; cell therapy; epigenetic memory; fetal tissue; iPSC; striatal differentiation.
Copyright © 2020 International Society for Cell & Gene Therapy. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors have no commercial, proprietary or financial interest in the products or companies described in this article.
Figures



Similar articles
-
Reprogrammed human lateral ganglionic eminence precursors generate striatal neurons and restore motor function in a rat model of Huntington's disease.Stem Cell Res Ther. 2024 Nov 22;15(1):448. doi: 10.1186/s13287-024-04057-9. Stem Cell Res Ther. 2024. PMID: 39578834 Free PMC article.
-
Robust Induction of DARPP32-Expressing GABAergic Striatal Neurons from Human Pluripotent Stem Cells.Methods Mol Biol. 2018;1780:585-605. doi: 10.1007/978-1-4939-7825-0_27. Methods Mol Biol. 2018. PMID: 29856037
-
Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.Mol Brain. 2012 May 21;5:17. doi: 10.1186/1756-6606-5-17. Mol Brain. 2012. PMID: 22613578 Free PMC article.
-
Challenges in progressing cell therapies to the clinic for Huntington's disease: A review of the progress made with pluripotent stem cell derived medium spiny neurons.Int Rev Neurobiol. 2022;166:1-48. doi: 10.1016/bs.irn.2022.09.003. Epub 2022 Oct 8. Int Rev Neurobiol. 2022. PMID: 36424090 Review.
-
Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy.Mol Neurobiol. 2016 Dec;53(10):6698-6708. doi: 10.1007/s12035-015-9601-8. Epub 2015 Dec 10. Mol Neurobiol. 2016. PMID: 26659595 Free PMC article. Review.
Cited by
-
Molecular Components of Store-Operated Calcium Channels in the Regulation of Neural Stem Cell Physiology, Neurogenesis, and the Pathology of Huntington's Disease.Front Cell Dev Biol. 2021 Apr 1;9:657337. doi: 10.3389/fcell.2021.657337. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33869222 Free PMC article. Review.
-
Clinical Potential of Cellular Material Sources in the Generation of iPSC-Based Products for the Regeneration of Articular Cartilage.Int J Mol Sci. 2023 Sep 22;24(19):14408. doi: 10.3390/ijms241914408. Int J Mol Sci. 2023. PMID: 37833856 Free PMC article. Review.
-
Differential chondrogenic differentiation between iPSC derived from healthy and OA cartilage is associated with changes in epigenetic regulation and metabolic transcriptomic signatures.Elife. 2023 Jan 30;12:e83138. doi: 10.7554/eLife.83138. Elife. 2023. PMID: 36715686 Free PMC article.
-
Do foetal transplant studies continue to be justified in Huntington's disease?Neuronal Signal. 2021 Dec 13;5(4):NS20210019. doi: 10.1042/NS20210019. eCollection 2021 Dec. Neuronal Signal. 2021. PMID: 34956650 Free PMC article. Review.
-
Human Induced Pluripotent Stem Cells: From Cell Origin, Genomic Stability, and Epigenetic Memory to Translational Medicine.Stem Cells. 2022 Jun 22;40(6):546-555. doi: 10.1093/stmcls/sxac020. Stem Cells. 2022. PMID: 35291013 Free PMC article. Review.
References
-
- Bates G., Tabrizi S., Jones L. Oxford University Press; UK: 2014. Huntington's disease (No. 64)
-
- Rosas H.D., Tuch D.S., Hevelone N.D., Zaleta A.K., Vangel M., Hersch S.M., Salat D.H. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov Disord. 2006;21:1317–1325. - PubMed
-
- Tabrizi S.J., Scahill R.I., Durr A., Roos R.A., Leavitt B.R., Jones R., Landwehrmeyer G.B., Fox N.C., Johnson H., Hicks S.L. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011;10:31–42. - PubMed
-
- Precious S.V., Kelly C.M. Transplantation in HD: are we transplanting the right cells? In: Tunalı N.E., editor. Huntington’s disease: molecular pathogenesis and current models. IntechOpen Ltd; London, UK: 2017. p. 119.
-
- Barker R.A., Mason S.L., Harrower T.P., Swain R.A., Ho A.K., Sahakian B.J., Mathur R., Elneil S., Thornton S., Hurrelbrink C. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. J Neurol Neurosurg Psychiatry. 2013;84:657–665. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials